178 related articles for article (PubMed ID: 25415291)
1. Time to initiation of antiretroviral therapy among patients who Are ART eligible in Rwanda: improvement over time.
Teasdale CA; Wang C; Francois U; Ndahimana Jd; Vincent M; Sahabo R; El-Sadr WM; Abrams EJ;
J Acquir Immune Defic Syndr; 2015 Mar; 68(3):314-21. PubMed ID: 25415291
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for delayed initiation of combination antiretroviral therapy in rural north central Nigeria.
Aliyu MH; Blevins M; Parrish DD; Megazzini KM; Gebi UI; Muhammad MY; Ahmed ML; Hassan A; Shepherd BE; Vermund SH; Wester CW
J Acquir Immune Defic Syndr; 2014 Feb; 65(2):e41-9. PubMed ID: 23727981
[TBL] [Abstract][Full Text] [Related]
3. Trends in and correlates of CD4+ cell count at antiretroviral therapy initiation after changes in national ART guidelines in Rwanda.
Mutimura E; Addison D; Anastos K; Hoover D; Dusingize JC; Karenzie B; Izimukwiye I; Mutesa L; Nsanzimana S; Nash D;
AIDS; 2015 Jan; 29(1):67-76. PubMed ID: 25562492
[TBL] [Abstract][Full Text] [Related]
4. HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries.
Tymejczyk O; Brazier E; Yiannoutsos C; Wools-Kaloustian K; Althoff K; Crabtree-Ramírez B; Van Nguyen K; Zaniewski E; Dabis F; Sinayobye JD; Anderegg N; Ford N; Wikramanayake R; Nash D;
PLoS Med; 2018 Mar; 15(3):e1002534. PubMed ID: 29570723
[TBL] [Abstract][Full Text] [Related]
5. Quantifying retention during pre-antiretroviral treatment in a large urban clinic in Uganda.
Castelnuovo B; Musaazi J; Musomba R; Ratanshi RP; Kiragga AN
BMC Infect Dis; 2015 Jul; 15():252. PubMed ID: 26126616
[TBL] [Abstract][Full Text] [Related]
6. Expansion and scale-up of HIV care and treatment services in four countries over ten years.
Teasdale CA; Abrams EJ; Yuengling KA; Lamb MR; Wang C; Vitale M; Hawken M; Melaku Z; Nuwagaba-Biribonwoha H; El-Sadr WM
PLoS One; 2020; 15(4):e0231667. PubMed ID: 32298331
[TBL] [Abstract][Full Text] [Related]
7. High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004-2012.
Agolory SG; Auld AF; Odafe S; Shiraishi RW; Dokubo EK; Swaminathan M; Dalhatu I; Onotu D; Abiri O; Debem H; Bashorun A; Ellerbrock TV
PLoS One; 2017; 12(9):e0183823. PubMed ID: 28863160
[TBL] [Abstract][Full Text] [Related]
8. Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia.
Mody A; Sikazwe I; Czaicki NL; Wa Mwanza M; Savory T; Sikombe K; Beres LK; Somwe P; Roy M; Pry JM; Padian N; Bolton-Moore C; Holmes CB; Geng EH
PLoS Med; 2018 Jun; 15(6):e1002574. PubMed ID: 29870531
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes of adult Ethiopian patients enrolled in HIV care and treatment: a multi-clinic observational study.
Melaku Z; Lamb MR; Wang C; Lulseged S; Gadisa T; Ahmed S; Habtamu Z; Alemu H; Assefa T; Abrams EJ
BMC Public Health; 2015 May; 15():462. PubMed ID: 25934178
[TBL] [Abstract][Full Text] [Related]
10. ART initiation in an outpatient treatment center in Dakar, Senegal: A retrospective cohort analysis (1998-2015).
Ngom NF; Faye MA; Ndiaye K; Thiam A; Ndour CT; Etard JF; Sow PS; Seydi M; Delaporte E; Cournil A
PLoS One; 2018; 13(9):e0202984. PubMed ID: 30231075
[TBL] [Abstract][Full Text] [Related]
11. Determinants of mortality and loss to follow-up among adults enrolled in HIV care services in Rwanda.
Mugisha V; Teasdale CA; Wang C; Lahuerta M; Nuwagaba-Biribonwoha H; Tayebwa E; Ingabire E; Ingabire P; Sahabo R; Twyman P; Abrams EJ;
PLoS One; 2014; 9(1):e85774. PubMed ID: 24454931
[TBL] [Abstract][Full Text] [Related]
12. High attrition before and after ART initiation among youth (15-24 years of age) enrolled in HIV care.
Lamb MR; Fayorsey R; Nuwagaba-Biribonwoha H; Viola V; Mutabazi V; Alwar T; Casalini C; Elul B
AIDS; 2014 Feb; 28(4):559-68. PubMed ID: 24076661
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral treatment scale-up among persons living with HIV in Kenya: results from a nationally representative survey.
Odhiambo JO; Kellogg TA; Kim AA; Ng'ang'a L; Mukui I; Umuro M; Mohammed I; De Cock KM; Kimanga DO; Schwarcz S;
J Acquir Immune Defic Syndr; 2014 May; 66 Suppl 1(Suppl 1):S116-22. PubMed ID: 24732815
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of sociodemographic, clinical and therapeutic factors of HIV-infected individuals in Kinshasa at antiretroviral therapy initiation during 2006-2017.
Ngongo NM; Darcis G; Nanituna HS; Mambimbi MM; Maes N; Mashi ML; Bepouka Izizag B; Moutschen M; Lepira Bompeka F
PLoS One; 2021; 16(11):e0259073. PubMed ID: 34739506
[TBL] [Abstract][Full Text] [Related]
15. Impact of early antiretroviral therapy eligibility on HIV acquisition: household-level evidence from rural South Africa.
Oldenburg CE; Bor J; Harling G; Tanser F; Mutevedzi T; Shahmanesh M; Seage GR; De Gruttola V; Mimiaga MJ; Mayer KH; Pillay D; Bärnighausen T
AIDS; 2018 Mar; 32(5):635-643. PubMed ID: 29334546
[TBL] [Abstract][Full Text] [Related]
16. Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.
Nsanzimana S; Remera E; Kanters S; Forrest JI; Ford N; Condo J; Binagwaho A; Bucher H; Thorlund K; Vitoria M; Mills EJ
Lancet HIV; 2015 Sep; 2(9):e376-84. PubMed ID: 26423551
[TBL] [Abstract][Full Text] [Related]
17. Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006-2011: findings from four sub-saharan African countries.
Lahuerta M; Wu Y; Hoffman S; Elul B; Kulkarni SG; Remien RH; Nuwagaba-Biribonwoha H; El-Sadr W; Nash D; ;
Clin Infect Dis; 2014 Feb; 58(3):432-41. PubMed ID: 24198226
[TBL] [Abstract][Full Text] [Related]
18. CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings.
Carter RJ; Dugan K; El-Sadr WM; Myer L; Otieno J; Pungpapong N; Toro PL; Abrams EJ;
J Acquir Immune Defic Syndr; 2010 Nov; 55(3):404-10. PubMed ID: 20595905
[TBL] [Abstract][Full Text] [Related]
19. The clock is ticking: the rate and timeliness of antiretroviral therapy initiation from the time of treatment eligibility in Kenya.
Odeny TA; DeCenso B; Dansereau E; Gasasira A; Kisia C; Njuguna P; Haakenstad A; Gakidou E; Duber HC
J Int AIDS Soc; 2015; 18(1):20019. PubMed ID: 26507824
[TBL] [Abstract][Full Text] [Related]
20. Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa.
McGrath N; Lessells RJ; Newell ML
HIV Med; 2015 Sep; 16(8):512-8. PubMed ID: 25959724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
